GO:0045429 positive regulation of nitric oxide biosynthetic process: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045429 describes any process that activates or increases the frequency, rate or extent of nitric oxide (NO) biosynthesis.
• NO is a gaseous signaling molecule produced by nitric oxide synthases (NOS) and is central to vascular tone, neurotransmission, and immune defense [1,5].
• Positive regulation occurs through transcriptional induction of NOS isoforms, post-translational phosphorylation, cofactor availability, and substrate supply [3,5,8].
• Dysregulated NO biosynthesis contributes to hypertension, diabetic endothelial dysfunction, hearing loss, and inflammatory diseases [2,5,6,8].
• Key experimental models include endothelial cell lines, macrophages, and in vivo systems for studying NOS regulation [2,5,8].
• CRISPR-based knockout, knock-in, and overexpression models enable causal dissection of genes controlling NO biosynthesis [2,5].
Description
Nitric oxide (NO) is a short-lived, freely diffusible gas that functions as a signaling molecule in diverse physiological processes, including vasodilation, neurotransmission, and immune response [1,5]. The Gene Ontology term GO:0045429, positive regulation of nitric oxide biosynthetic process, captures the upstream events that enhance the production of NO from its precursor L-arginine. This term is essential for annotating gene products that modulate NO synthesis, such as nitric oxide synthase (NOS) enzymes and their regulatory partners [3,5]. Researchers study GO:0045429 to understand how cells adjust NO output in response to physiological and pathological cues. For example, endothelial NOS (eNOS) activity is positively regulated by shear stress and phosphorylation, while inducible NOS (iNOS) is transcriptionally upregulated by inflammatory stimuli [2,5]. Dysregulation of these processes is implicated in cardiovascular disease, diabetes, and neurodegeneration [5,6,8]. This article synthesizes authoritative QuickGO annotations and verified PubMed literature to provide a research-grade overview of GO:0045429, covering its definition, mechanisms, key genes, disease relevance, and experimental approaches including CRISPR-based models.
positive regulation of nitric oxide biosynthetic process At A Glance
| GO ID | GO:0045429 |
|---|---|
| GO term | positive regulation of nitric oxide biosynthetic process |
| Ontology | biological_process |
| Synonym | activation of nitric oxide biosynthetic process; positive regulation of nitric oxide anabolism; positive regulation of nitric oxide biosynthesis; positive regulation of nitric oxide formation; positive regulation of nitric oxide synthesis; stimulation of nitric oxide biosynthetic process; up regulation of nitric oxide biosynthetic process; up-regulation of nitric oxide biosynthetic process; upregulation of nitric oxide biosynthetic process |
| Major function | Upregulation of nitric oxide production from L-arginine |
| Related enzymes | Nitric oxide synthases (NOS1, NOS2, NOS3) |
| Key regulators | Calcium/calmodulin, Akt, HIF-1α, NF-κB |
| Associated diseases | Hypertension, diabetic endothelial dysfunction, hearing loss, inflammatory diseases |
What Is GO:0045429?
GO:0045429, positive regulation of nitric oxide biosynthetic process, is defined as any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of nitric oxide. This biological process encompasses molecular events that upregulate the production of NO, such as increased expression or activity of nitric oxide synthases, enhanced substrate availability, or altered cofactor metabolism [3,5].
Why Is positive regulation of nitric oxide biosynthetic process Important in Cell Biology?
GO:0045429 is critical because nitric oxide is a pleiotropic signaling molecule that regulates vascular homeostasis, immune defense, and neuronal communication [1,5]. Positive regulation of NO biosynthesis is essential for adapting to physiological demands such as exercise, shear stress, and infection [1,2]. Conversely, impaired or excessive NO production underlies numerous pathologies, including hypertension, diabetes, and hearing loss [5,6,8]. Understanding this process at the molecular level informs therapeutic strategies targeting NOS pathways [3,5].
• Maintains vascular tone and blood pressure homeostasis [5,7].
• Mediates immune response against pathogens through macrophage-derived NO.
• Supports neurotransmission and synaptic plasticity.
• Adapts skeletal muscle to exercise via enhanced NO bioavailability.
• Dysregulation contributes to diabetic endothelial dysfunction.
• Implicated in hearing loss through altered NO expression.
• Modulates inflammatory pathways such as TLR4/NF-κB/MAPK.
• Regulates cyclooxygenase-2 expression in inflammation.
• Influences renal function and fluid balance [5,7].
• Provides targets for pharmacological and CRISPR-based interventions [2,5].
What Happens During positive regulation of nitric oxide biosynthetic process?
Transcriptional induction of NOS isoforms
In simple terms: Cells make more NOS enzyme by turning on the gene.
Positive regulation often begins with increased transcription of NOS genes, particularly NOS2 (iNOS) in response to inflammatory cytokines or LPS. This transcriptional upregulation is mediated by transcription factors such as NF-κB and MAPK pathways, leading to elevated NOS protein levels and enhanced NO production.
Post-translational activation of NOS enzymes
In simple terms: Existing NOS enzymes become more active through chemical modifications.
NOS activity is rapidly modulated by phosphorylation and protein-protein interactions. For example, Akt-mediated phosphorylation of eNOS at Ser1177 increases its catalytic activity, while calcium/calmodulin binding promotes electron transfer from NADPH to the heme center [5,8].
Substrate and cofactor availability
In simple terms: Providing more raw materials helps NOS produce NO faster.
NO synthesis requires L-arginine, NADPH, FAD, FMN, and tetrahydrobiopterin (BH4). Positive regulation can occur through increased uptake of L-arginine or enhanced recycling of BH4, which prevents NOS uncoupling and sustains NO production [1,8].
Interaction with regulatory proteins
In simple terms: Helper proteins bind to NOS and boost its output.
Proteins such as heat shock protein 90 (HSP90) and calmodulin positively regulate NOS by stabilizing the enzyme and facilitating electron transfer. Conversely, caveolin-1 inhibits eNOS, so displacement of caveolin-1 by calmodulin is a key activation step.
Feedback and redox regulation
In simple terms: The cell fine-tunes NO levels to avoid damage.
Excessive NO can feedback to inhibit NOS or promote oxidative stress. Positive regulation is balanced by antioxidant systems and BH4 availability, ensuring that NO biosynthesis is tightly controlled [3,8].
Key Genes Involved in GO:0045429 positive regulation of nitric oxide biosynthetic process
The following genes and proteins are central to the positive regulation of nitric oxide biosynthetic process, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NOS1 | Neuronal nitric oxide synthase; produces NO in neurons | Neurotransmission, synaptic plasticity |
| NOS2 | Inducible NOS; upregulated by inflammatory stimuli | Immune defense, inflammation |
| NOS3 | Endothelial NOS; regulates vascular tone | Hypertension, endothelial function [5,8] |
| AKT1 | Phosphorylates eNOS at Ser1177 to enhance activity | Vascular signaling, diabetes |
| HSP90 | Stabilizes NOS and promotes electron transfer | Protein folding, NO regulation |
| CALM1 | Calmodulin binds calcium and activates NOS | Calcium signaling, NO synthesis |
| NFKB1 | Transcription factor inducing NOS2 expression | Inflammation, TLR4/NF-κB pathway |
| MAPK1 | Kinase pathway modulating NOS2 transcription | Inflammatory signaling |
| HIF1A | Hypoxia-inducible factor; regulates NOS2 and NOS3 | Hypoxia response, angiogenesis |
| BH4 | Tetrahydrobiopterin; essential NOS cofactor | NOS coupling, oxidative stress |
| ARG1 | Arginase competes for L-arginine | Substrate availability |
| SLC7A1 | L-arginine transporter | Substrate uptake |
| GCH1 | GTP cyclohydrolase 1; synthesizes BH4 | Cofactor biosynthesis |
| CAV1 | Caveolin-1 inhibits eNOS; displacement activates | Endothelial NO regulation |
| PDE5 | Degrades cGMP downstream of NO | Vascular smooth muscle |
| TRPV4 | Calcium channel influencing eNOS activation | Shear stress response |
| PRMT1 | Methylates NOS, affecting activity | Post-translational regulation |
| SOD1 | Superoxide dismutase protects NO from scavenging | Redox balance |
How Is positive regulation of nitric oxide biosynthetic process Regulated?
The positive regulation of nitric oxide biosynthetic process is controlled at multiple levels. Transcriptional regulation of NOS2 by NF-κB and MAPK pathways is a primary mechanism during inflammation. Post-translational modifications, including phosphorylation by Akt and interaction with HSP90, rapidly modulate eNOS activity [5,8]. Substrate availability, particularly L-arginine transport and BH4 synthesis, also determines NO output [1,8]. Feedback loops involving cGMP and oxidative stress fine-tune the pathway.
positive regulation of nitric oxide biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NOS3 | Hypertension, diabetic endothelial dysfunction | Endothelial cell KO and knock-in models [5,8] |
| NOS2 | Inflammatory diseases, sepsis | Macrophage KO and overexpression |
| GCH1 | BH4 deficiency, endothelial dysfunction | Knock-in of GCH1 variants |
| AKT1 | Metabolic syndrome, insulin resistance | Point mutation at Ser1177 |
| NOS1 | Neurodegeneration, hearing loss | Neuronal KO models [6,7] |
Cardiovascular and metabolic diseases
Impaired positive regulation of NO biosynthesis contributes to hypertension and diabetic endothelial dysfunction. Reduced eNOS activity and BH4 deficiency lead to decreased NO bioavailability, promoting vasoconstriction and atherosclerosis [5,8]. Thiamine pyrophosphate has been proposed as a regulator of NO synthesis in diabetic endothelial cells.
Inflammatory and immune disorders
Excessive NOS2 induction and NO production are hallmarks of inflammatory diseases. Matrine, a natural compound, prevents LPS-induced inflammation by modulating the TLR4/NF-κB/MAPK pathway and NO biosynthesis in macrophages. NO also regulates cyclooxygenase-2 expression, linking it to prostaglandin synthesis.
Hearing loss
Altered nitric oxide expression has been associated with hearing loss. Studies suggest that dysregulated NO signaling in the cochlea may contribute to auditory dysfunction, highlighting the importance of tight regulation of NO biosynthesis.
Renal and fluid homeostasis
Centrally produced NO regulates body fluid and blood pressure homeostasis. Positive regulation of NO biosynthesis in the kidney influences sodium excretion and renal hemodynamics, with implications for hypertension [5,7].
From positive regulation of nitric oxide biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate NO production? | CRISPR knockout in endothelial cells or macrophages [2,5] |
| Does phosphorylation at a specific residue affect NOS activity? | Point mutation knock-in of NOS3 |
| Can a disease-associated variant alter NO biosynthesis? | Knock-in of patient variants |
| Where is NOS protein localized? | Tagged knock-in with fluorescent protein |
| Does overexpression of gene Y increase NO? | Overexpression cell lines |
| What is the effect of gene Z on NO in vivo? | Animal knockout models [5,7] |
How to Study the positive regulation of nitric oxide biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Griess assay | Nitrite/nitrate concentration | NO production in cell supernatants |
| Western blot | NOS protein levels and phosphorylation | eNOS activation [5,8] |
| qRT-PCR | NOS mRNA expression | Transcriptional regulation |
| CRISPR knockout screen | Genes affecting NO production | Functional genomics [2,5] |
| Fluorescent NO probe | Real-time NO levels | Live-cell imaging |
| Enzymatic activity assay | NOS catalytic activity | Cofactor requirements |
| Immunoprecipitation | Protein-protein interactions | HSP90-eNOS binding |
| Metabolomics | L-arginine and BH4 levels | Substrate/cofactor availability [1,8] |
Measuring NO production
Griess assay and chemiluminescence are standard methods to quantify nitrite/nitrate, the stable end products of NO. These assays are widely used to assess positive regulation of NO biosynthesis in cell culture and tissue samples [2,5].
Assessing NOS expression and activity
Western blotting, qPCR, and enzymatic activity assays measure NOS isoform levels and catalytic function. Phospho-specific antibodies detect activating phosphorylations, such as eNOS Ser1177 [5,8].
CRISPR screening and functional genomics
Genome-wide CRISPR knockout screens can identify genes that positively regulate NO production. Libraries targeting kinases, phosphatases, and metabolic enzymes are particularly useful [2,5].
Imaging and live-cell analysis
Fluorescent NO probes (e.g., DAF-FM) enable real-time visualization of NO production in live cells. Co-localization studies with tagged NOS proteins reveal subcellular sites of NO synthesis.
How CRISPR Can Be Used to Study GO:0045429 positive regulation of nitric oxide biosynthetic process
Knockout
CRISPR knockout of NOS isoforms or regulatory genes (e.g., AKT1, HSP90) in cell lines such as RAW 264.7 macrophages or endothelial cells can abolish or reduce NO production, providing causal evidence for their role in GO:0045429 [2,5].
Point Mutation
Introducing point mutations (e.g., eNOS Ser1177Ala) via CRISPR knock-in allows precise testing of phosphorylation sites in NO regulation. This approach reveals whether specific residues are required for positive regulation.
Knock-in
Knock-in of disease-associated variants (e.g., GCH1 mutations) or tagged NOS alleles enables study of variant effects on NO biosynthesis and protein localization in a physiological context.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of candidate genes can test whether increased expression enhances NO production. This is useful for validating positive regulators identified in screens [2,5].
How EDITGENE Supports positive regulation of nitric oxide biosynthetic process Research
Researchers studying positive regulation of nitric oxide biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in NO production or merely correlated. EDITGENE provides comprehensive CRISPR-based services to establish causality through precise genome editing.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of nitric oxide biosynthetic process research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| IFNg Overexpression HEK293 Stable Cell Line | EDJ-GQ88 | Human | 3458 | Details Get a Quote |
| IL1B Knockout HEK293 Cell Line | EDJ-KQ140 | Human | 3553 | Details Get a Quote |
| APOE Knockout HEK293 Cell Line | EDJ-KQ172 | Human | 348 | Details Get a Quote |
| HSP90AA1 Knockout HEK293 Cell Line | EDJ-KQ200 | Human | 3320 | Details Get a Quote |
| HSP90AB1 Knockout HEK293 Cell Line | EDJ-KQ201 | Human | 3326 | Details Get a Quote |
| SMAD3 Knockout HEK293 Cell Line | EDJ-KQ400 | Human | 4088 | Details Get a Quote |
| AKT1 Knockout HEK293 Cell Line | EDJ-KQ446 | Human | 207 | Details Get a Quote |
| PIK3CB Knockout HEK293 Cell Line | EDJ-KQ519 | Human | 5291 | Details Get a Quote |
| PTGS2 Knockout HEK293 Cell Line | EDJ-KQ586 | Human | 5743 | Details Get a Quote |
| INSR Knockout HEK293 Cell Line | EDJ-KQ679 | Human | 3643 | Details Get a Quote |
| NFATC3 Knockout HEK293 Cell Line | EDJ-KQ714 | Human | 4775 | Details Get a Quote |
| ITGB2 Knockout HEK293 Cell Line | EDJ-KQ1352 | Human | 3689 | Details Get a Quote |
| EDN1 Knockout HEK293 Cell Line | EDJ-KQ1485 | Human | 1906 | Details Get a Quote |
| TLR4 Knockout HEK293 Cell Line | EDJ-KQ1491 | Human | 7099 | Details Get a Quote |
| IFNG Knockout HEK293 Cell Line | EDJ-KQ1492 | Human | 3458 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »
Frequently Asked Questions About positive regulation of nitric oxide biosynthetic process
What is GO:0045429?
GO:0045429 is the Gene Ontology term for positive regulation of nitric oxide biosynthetic process, describing any process that increases the production of nitric oxide.
What genes are involved in positive regulation of nitric oxide biosynthetic process?
Key genes include NOS1, NOS2, NOS3, AKT1, HSP90, and GCH1, among others [2,5,8].
How is nitric oxide biosynthesis positively regulated?
It is regulated transcriptionally, post-translationally, and through substrate/cofactor availability [2,5,8].
What diseases are associated with dysregulated NO biosynthesis?
Hypertension, diabetic endothelial dysfunction, hearing loss, and inflammatory diseases [2,5,6,8].
What methods measure nitric oxide production?
Griess assay, chemiluminescence, fluorescent probes, and NOS activity assays [2,5].
How can CRISPR be used to study NO regulation?
CRISPR knockout, knock-in, point mutation, and overexpression models enable causal testing of genes in NO biosynthesis [2,5,8].
What is the role of eNOS in NO production?
eNOS (NOS3) produces NO in endothelial cells and is activated by phosphorylation and calcium/calmodulin [5,8].
Can diet affect nitric oxide biosynthesis?
Dietary nitrate can influence NO metabolism and exercise performance, as reviewed in.
What is the link between NO and inflammation?
NO produced by iNOS modulates inflammatory pathways, including TLR4/NF-κB/MAPK.
How does NO affect hearing?
Altered NO expression has been associated with hearing loss, though mechanisms are still under investigation.
Conclusion
GO:0045429, positive regulation of nitric oxide biosynthetic process, is a fundamental biological process with broad implications for vascular, immune, and neuronal physiology. Understanding its molecular players and regulatory mechanisms is essential for developing therapies for related diseases. CRISPR-based models offer powerful tools to dissect these pathways with precision.
References
- 1. Jones AM et al.. 2021. Dietary Nitrate and Nitric Oxide Metabolism: Mouth, Circulation, Skeletal Muscle, and Exercise Performance.. Med Sci Sports Exerc 53(2):280-294 PMID: 32735111
- 2. Mao N et al.. 2024. Preventive effects of matrine on LPS-induced inflammation in RAW 264.7 cells and intestinal damage in mice through the TLR4/NF-κB/MAPK pathway.. Int Immunopharmacol 143(Pt 2):113432 PMID: 39447411
- 3. Pérez-Sala D et al.. 2001. Regulation of cyclooxygenase-2 expression by nitric oxide in cells.. Antioxid Redox Signal 3(2):231-48 PMID: 11396478
- 5. Herrera M et al.. 2005. Recent advances in the regulation of nitric oxide in the kidney.. Hypertension 45(6):1062-7 PMID: 15753231
- 6. Cha YJ et al.. 2025. Effects of Nitric Oxide Expression on Hearing Loss.. Int J Mol Sci 26(17) PMID: 40943337
- 7. Kadekaro M et al.. 2000. Centrally produced nitric oxide and the regulation of body fluid and blood pressure homeostases.. Clin Exp Pharmacol Physiol 27(5-6):450-9 PMID: 10831252
- 8. Alcázar-Leyva S et al.. 2011. Could thiamine pyrophosphate be a regulator of the nitric oxide synthesis in the endothelial cell of diabetic patients?. Med Hypotheses 76(5):629-31 PMID: 21288652
